Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer
- First Online:
- 368 Downloads
Goals of work
Fear of cancer recurrence (FOR) is common in prostate cancer patients, but little research has examined the impact of FOR on quality of life (QOL) or the mechanism by which these fears become intensified. The objective of this study was to examine treatment satisfaction (TS) as a moderator of the relationship between FOR and QOL.
Patients and methods
Data were drawn from the CaPSURE™ database, a 12,000-man national observational prostate cancer registry. Three hundred and thirty-three patients who underwent radical prostatectomy (RP) to treat their prostate cancer completed self-report measures. TS was measured 0–6 months post-RP with a nine-item scale developed for this study, FOR was measured 6–12 months post-RP with a previously validated five-item scale, and QOL was measured 12–18 months post-RP with the Short Form 36.
After controlling for age, education, number of comorbid medical conditions, and cancer severity, lower FOR (B = −0.12, p < 0.0001), higher TS (B = 0.09, p < 0.001), and the interaction of TS × FOR (B = 0.87, p < 0.05) significantly predicted higher mental health QOL scores. Furthermore, lower FOR (B = −0.08, p < 0.01), and the interaction of TS × FOR (B = −1.11, p < 0.01) significantly predicted higher physical health QOL scores.
TS levels mitigated the impact of high FOR on lower levels of QOL. Specifically, patients who reported lower TS and greater FOR endorsed significantly lower levels of QOL compared to other patients in the sample.
KeywordsProstate cancer Treatment satisfaction Fear of recurrence Quality-of-life
- 1.American Cancer Society (2007) Cancer facts and figures. American Cancer Society, Atlanta, GAGoogle Scholar
- 9.Hill JM, Kornblith AB, Jones D, Freeman A, Holland JF, Glicksman AS et al (1998) A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 82:208–218PubMedCrossRefGoogle Scholar
- 13.Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R et al (1996) The CaPSURE™ database: a methodology for clinical practice and research in prostate cancer. CaPSURE™ Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48:773–777PubMedCrossRefGoogle Scholar
- 17.Mishel MH (1998) Uncertainty in illness. Image 20:225–232Google Scholar
- 20.Roth A, Nelson CJ, Rosenfeld B, Warshowski A, O’Shea N, Scher H, Holland JC, Slovin S, Curley-Smart T, Reynolds T, Breitbart W (2006) Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics 47:340–347PubMedCrossRefGoogle Scholar
- 24.Ware JE Jr, Losinski M (2001) The SF-36 physical & mental health summary scales: a manual for users of version 1, 2nd edn. QualityMetric, Lincoln, RIGoogle Scholar